CancerNetwork® Face-Off

Experts discuss a dynamic and multifaceted debate on frontline and subsequent treatment strategies for EGFR-mutant non–small cell lung cancer (NSCLC), addressing the promise and challenges of combination therapies, central nervous system efficacy, long-term tolerability, sequencing complexities, and patient-centered decision-making in complex clinical scenarios to optimize outcomes amid evolving evidence and real-world considerations.

Panelists discuss how to optimize treatment approaches for patients with lower-risk myelodysplastic syndrome through a competitive debate format covering luspatercept vs erythropoiesis-stimulating agents as first-line therapy, management of super-responders, timing of treatment initiation, and real-world evidence from recent clinical trials including COMMANDS, MEDALIST, and IMerge.

Panelists discuss various aspects of lower-risk myelodysplastic syndromes, including trial results on erythropoiesis-stimulating agent timing and novel agents like luspatercept and imetelstat, treatment sequencing and timing debates, personalized approaches based on erythropoietin levels, and complex case management balancing immediate symptom relief with long-term strategies.

Amer Zeidan, MBBS; Catherine Lai, MD; Bart Scott, MD; Andrew Brunner, MD; Jonathan Abbas, MD; Akriti Jain, MD; Mohamed Hegazi, MD; Somedeb Ball, MBBS; and Salman Fazal, MD, examine critical clinical decisions in myelodysplastic syndrome management, including optimal sequencing of erythropoiesis-stimulating agents vs luspatercept, dosing strategies, and efficacy data from pivotal trials such as MEDALIST, IMerge, and ELEMENT-MDS, which demonstrate improvements in transfusion burden and hemoglobin levels.

Panelists discuss how emerging therapies like CC-486, venetoclax, and menin inhibitors are reshaping treatment strategies for relapsed and refractory acute myeloid leukemia while debating the role of posttransplant maintenance and personalized approaches based on genetic mutations such as NPM1 and TP53.

Experts examine diverse aspects of bispecific antibody therapies in relapsed/refractory multiple myeloma, including clinical trial results, combination strategies, dosing considerations, sequencing with CAR T-cell therapy, prophylactic measures, outpatient administration, and implementation in community settings, to optimize patient outcomes and treatment approaches.

Experts examine cutting-edge treatments, clinical trial results, and personalized approaches for managing relapsed/refractory multiple myeloma, focusing on novel therapies like CAR T-cells, bispecific antibodies, and their optimal sequencing to improve patient outcomes.

Experts from University of California San Diego and City of Hope discuss and debate treatment practices for patients with advanced non–small cell lung cancer.

Experts from Northwestern University and the University of Chicago present data and debate treatment practices in the non–small cell lung cancer space.

A panel of experts analyzed and discussed phase 2&3 trial findings on efficacy and safety of emerging targeted therapies such as ADCs, bispecific, and CAR-T cells for relapsed/ refractory blood cancers.

A panel of experts analyzed and discussed phase 2&3 trial findings on efficacy and safety of emerging targeted therapies such as ADCs, bispecific, and CAR-T cells for relapsed/ refractory blood cancers.

A team of experts discuss multiple topics related to non-small cell lung cancer.

A panel of experts discussing treatment for ALK positive for non-small cell malignancies.

Two teams from Karmanos Cancer Institute and Cleveland Clinic debate and discuss recent data in the chronic myeloid leukemia treatment landscape.

Two teams from Karmanos Cancer Institute and Cleveland Clinic debate and discuss recent data in the multiple myeloma treatment landscape.

Experts from the Fred Hutchinson Cancer Center and City of Hope form two teams and go head-to-head in this review of the latest datasets in the multiple myeloma treatment landscape.

Experts from the Fred Hutchinson Cancer Center and City of Hope form two teams and go head-to-head in this review of the latest datasets in the chronic myeloid leukemia treatment landscape.

Two teams from leading institutions, UT Southwestern and the Mayo Clinic, go head-to-head to review the latest datasets in chronic myeloid leukemia management.

Two teams from leading institutions, UT Southwestern and the Mayo Clinic, go head-to-head to review the latest datasets in multiple myeloma management.

As part of its Face-Off video series, CancerNetwork spoke with Ravi Vij, MD, MBA, from Washington University School of Medicine.

Two teams from leading institutions go head-to-head to debate the latest datasets and advances in multiple myeloma.

Two teams from leading institutions go head-to-head to debate the latest datasets and advances in chronic myeloid leukemia (CML).

In a new series from CancerNetwork®, two teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.